Samsung Biologics Awarded the Terra Carta Seal for Ensuring a Sustainable Future

Samsung Biologics has been awarded The Terra Carta Seal from the sustainable markets initiative.

The Terra Carta itself is a recovery plan, launched in January 2021, to help nature, people and planet. The companies that are awarded the Terra Carta Seal must have their aims aligned with the plan, to encourage working together as a collective to achieve these goals. 

Samsung Biologics has already established its commitment to fighting global warming with its goal of hitting net zero greenhouse gas emissions across its direct operations and supply chain by 2050 or earlier. As a CDMO that offers large capacity development and manufacturing of biologics products, the company has had to have a rigorous environmental management strategy to help to reduce emissions from their bioprocessing procedures. Some of these strategies include process energy optimization, transitioning to 100% renewable energy by investing in solar panels (as part of the Climate Group’s RE100 initiative) and utilizing external resources, converting to zero emission vehicles, and minimising the use of disposables in the manufacturing process through waste management and recycling. 

John Rim, CEO and President, Samsung Biologics commented: “We are honoured to be recognized with the Terra Carta Seal by the Sustainable Markets Initiative for Samsung Biologics’ contribution in working alongside our industry peers for this global effort. Healthcare is at a pivotal moment and through our collaborative efforts, we can contribute to shaping climate-resilient practices to influence and help shape policy across the pharmaceutical and healthcare sectors.”

Brian Moynihan, Co-Chair, Sustainable Markets Initiative stated: “The SMI brings CEOs together to work on the shared goals of accelerating our transition to a sustainable future.  I congratulate those organisations recognized with the 2022 Terra Carta Seal and thank them for their commitment to sustainable markets.”

The Terra Carta Seal takes into account the challenges of each industry as they strive towards a more sustainable future and hope to support them in this journey so that we can reach a 1.5-degree target more quickly. 

Samsung Biologics, committed to this mutual goal is encouraging its suppliers as part of an initiative under the Supply Chains Working Group within the Sustainable Markets Initiative’s Health Systems Task Force to identify targets for carbon reduction in the supply chain and achieving net zero. They have been continuing this work through COP27 building new partnerships and strategies.